Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
The securities were offered pursuant to an effective shelf registrationstatement filed by Cardium with the U.S. Securities and Exchange Commission.This press release does not constitute an offer to sell or the solicitation ofan offer to buy, and these securities may not be sold in any jurisdiction inwhich such offer, solicitation or sale would be unlawful prior to registrationor qualification under the securities laws of any such jurisdiction.
Advertisement
About Cardium
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc.and the Tissue Repair Company, are medical technology companies primarilyfocused on the development, manufacture and sale of innovative therapeuticproducts and devices for cardiovascular, ischemic and related indications.Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec,Ad5FGF4), is a DNA-based growth factor therapeutic being developed forpotential use by interventional cardiologists as a one-time treatment topromote and stimulate the growth of collateral circulation in the hearts ofpatients with ischemic conditions such as recurrent angina. For moreinformation about Cardium and its businesses, products and therapeuticcandidates, please visit http://www.cardiumthx.com or view its 2007 AnnualReport at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medicaltechnology company in the emerging field of patient temperature modulationtherapy to rapidly and controllably cool the body in order to reduce celldeath and damage following acute ischemic events such as cardiac arrest orstroke, and to potentially lessen or prevent associated injuries such asadverse neurological outcomes. For more information about Cardium's InnerCoolsubsidiary and patient temperature modulation, including InnerCool's CelsiusControl System(TM) and the CoolBlue(TM) System, please visithttp://www.innercool.com.
Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-basedbiopharmaceutical company focused on the development of growth factortherapeutics for the treatment of severe chronic diabetic wounds. TRC's leadproduct candidate, Excellarate(TM), is a DNA-activated collagen gel fortopical treatment formulated with an adenovector delivery carrier encodinghuman platelet-derived growth factor-BB (PDGF-BB). Excellarate is initiallybeing developed to be administered once or twice for the potential treatmentof non-healing diabetic foot ulcers. Other potential applications for TRC'sGene Activated Matrix(TM) (GAM(TM)) technology include therapeuticangiogenesis (cardiovascular ischemia, peripheral arterial disease) andorthopedic products, including hard tissue (bone) and soft tissue (ligament,tendon, cartilage) repair. For more information about Cardium's Tissue RepairCompany subsidiary, please visit http://www.t-r-co.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in thispress release are forward looking and reflect numerous assumptions and involvea variety of risks and uncertainties, many of which are beyond our control andmay cause actual results to differ materially from stated expec